Premium
A phase I study of hepatic arterial infusion using difluoromethylornithine
Author(s) -
Lipton Allan,
Harvey Harold A.,
Glenn Jerry,
Weidner William A.,
Strauss Melvin,
Miller Sharon E.,
Taylor Jerlynn B.,
WhiteHershey Deborah,
Barlow John L. R.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890201)63:3<433::aid-cncr2820630306>3.0.co;2-5
Subject(s) - medicine , hepatic arterial infusion , eflornithine , hepatic dysfunction , gastroenterology , anesthesia , pharmacology , cancer , metastasis , biochemistry , chemistry , enzyme , spermidine
Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m 2 .